Selected Publications
         Byron SA, Hendricks WPD, Nagulapally AB, Kraveka JM, Ferguson WS, Brown VI, Eslin DE, Mitchell D, Cornelius A, Roberts W, Isakoff MS, Oesterheld JE, Wada RK, Rawwas J, Neville K, Zage PE, Harrod VL, Bergendahl G, Van Sickle E, Dykema K, Bond J, Chou HC, Wei JS, Wen X, Reardon HV, Roos A, Nasser S, Izatt T, Enriquez D, Hegde AM, Cisneros F, Christofferson A, Turner B, Szelinger S, Keats JJ, Halperin RF, Khan J, Saulnier Sholler GL, Trent JM. 2022. Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion. Cancer Research. In press.  PMID: 34610968.       
         Foster, J., E. Barbieri, L. Zhang, K. Scorsone, M. Moreno-Smith, P. Zage, T.M. Horton.  2021. The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma.  International Journal of Molecular Sciences; 22: 6565.  PMID:  34207315
         Whittle, S., V. Smith, A. Silverstein, M. Parmeter, C Minard, M.B Bernhardt, P. Zage, R. Venkatramani, J. Nuchtern, A. Heczey, H. Russell, J. Shohet, J. Foster.  2020.  Is high risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors.  Pediatric Blood & Cancer; e28417.  PMID:  32729196
         Paul, M.R., Y. Huo, A. Liu, J. Lesperance, A. Garancher, R. Wechsler-Reya, P.E. Zage.  2020.  Characterization of G-CSF Receptor Expression in Medulloblastoma. Neuro-Oncology Advances; 2(1):  vdaa062.  PMID:  32642714
         Subramonian, D., N. Phanthilath, Y. Huo, S. Flynn, H. Rinehardt, J. Zhang, K. Messer, Q. Mo, S. Huang, J. Lesperance, P.E. Zage.  2020.  Regorafenib Is Effective Against Neuroblastoma in Vitro and in Vivo and Inhibits the RAS-MAPK, PI3K/Akt/mTOR, and Fos/Jun Pathways. British Journal of Cancer, 123(4):  568-579.  PMID: 32457362
         Phanhthilath N, Hakim S, Su C, Liu A, Subramonian D, Lesperance J, Zage PE. 2020.  Mechanisms of Efficacy of the FGFR1-3 Inhibitor AZD4547 in Pediatric Solid Tumor Models. Investigational New Drugs, 38(6): 1677-1686.  PMID: 32436058
         Adam K, Lesperance J, Hunter T, Zage PE. 2020.  The Potential Functional Roles of NME1 Histidine Kinase Activity in Neuroblastoma Pathogenesis. International Journal of Molecular Sciences, 21(9): 3319. PMID: 32392889
         Lewis EC, Kraveka JM, Ferguson W, Eslin D, Brown VI, Bergendahl G, Roberts W, Wada RK, Oesterheld J, Mitchell D, Foley J, Zage P, Rawwas J, Rich M, Lorenzi E, Broglio K, Berry D, Saulnier Sholler GL. 2020.  A Subset Analysis of a Phase II Trial Evaluating the Use of DFMO as Maintenance Therapy for High-Risk Neuroblastoma. International Journal of Cancer, 147 (11): 3152-9.  PMID:  32391579
         Aristizabal P, Sherer M, Castelao E, Thornburg CD, Proudfoot J, Jacobs E, Newfield R, Zage P, Roberts W, Martinez ME.  2020.  Sociodemographic and clinical characteristics associated with vitamin D status in newly diagnosed pediatric cancer patients. Pediatric Hematology and Oncology, 37(4):314-325. PMID:  32153233
         Flynn S, Lesperance J, Macias A, Phanhthilath N, Paul MR, Kim JW, Tamayo P, Zage PE.  2019.  The Multikinase Inhibitor RXDX-105 is Effective Against Neuroblastoma In Vitro and In Vivo. Oncotarget, 10(59): 6323-33.  PMID:  31695841; PMCID: PMC6824878
         Saulnier Sholler GL, Ferguson W, Bergendahl G, Bond JP, Neville K, Eslin D, Brown V, Roberts W, Wada RK, Oesterheld J, Mitchell D, Foley J, Parikh NS, Eshun F, Zage P, Rawwas J, Sencer S, Pankiewicz D, Quinn M, Rich M, Junewick J, Kraveka J.  2018.  Maintenance DFMO Increases Survival in High Risk Neuroblastoma.  Scientific Reports.  8:  14445.  PMID: 30262852
         Zage, P.E., S.B. Whittle, J.M. Shohet.  2017.  CD114:  A New Member of the Neural Crest-Derived Cancer Stem Cell Marker Family.  Journal of Cellular Biochemistry.  118(2):  221-31.  PMID:  27428599
         Whittle, S.B., K. Patel, L. Zhang, S.E. Woodfield, M. Du, V. Smith, P.E. Zage.  2016.  The Novel Kinase Inhibitor Ponatinib Is An Effective Antiangiogenic Agent Against Neuroblastoma.  Investigational New Drugs.  34(6): 685-92.  PMID:  27586230.
         Du, M., L. Zhang, K.A. Scorsone, S.E. Woodfield, P.E. Zage.  2016.  Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine.  Scientific Reports. 6, 27458.  PMID:  27282514.
         Woodfield, S.E., R. Guo, Y. Liu, A.M. Major, E.F. Hollingsworth, S.M. Indiviglio, S.B. Whittle, Q. Mo, A.J. Bean, M. Ittmann, D. Lopez-Terrada, and P.E. Zage.  2016.  Neuroblastoma patient outcomes, tumor differentiation, and ERK activation are correlated with expression levels of the ubiquitin ligase UBE4B.  Genes & Cancer.  7(1-2): 13-26.  PMID:  27014418.
         Woodfield, S.E., L. Zhang, K. Scorsone, Y. Liu, and P.E. Zage.  2016.  Binimetinib Inhibits MEK and Is Effective Against Neuroblastoma Tumor Cells With Low NF1 Expression.  BMC Cancer.  16: 172.  PMID:  26925841.
         Whittle, S., S. Reyes, M. Du, M. Gireud, L. Zhang, S.E. Woodfield, M. Ittmann, M. Scheurer, A.J. Bean, and P.E. Zage.  2016.  A Polymorphism in the FGFR4 Gene is associated with Risk of Neuroblastoma and Altered Receptor Degradation.  Journal of Pediatric Hematology/Oncology. 38(2):  131-8.  PMID:  26840079
          Zhang, L., K. Scorsone, S.E. Woodfield, and P.E. Zage.  2015.  Sensitivity of Neuroblastoma to the Novel Kinase Inhibitor Cabozantinib Is Mediated by ERK Inhibition.  Cancer Chemotherapy & Pharmacology.  76(5): 977-87.  PMID:  26407819
          Zhang, L., S. Agarwal, J.M. Shohet, and P.E. Zage.  2015.  CD114 Expression Mediates Melanoma Tumor Cell Growth and Treatment Resistance.  Anticancer Research.  35(7): 3787-92.  PMID: 26124323.
          Scorsone, K.S., L. Zhang, S.E. Woodfield, J. Hicks, and P.E. Zage.  2014.  The Novel Kinase Inhibitor EMD1214063 Is Effective Against Neuroblastoma.  Investigational New Drugs.  32: 815-24.  PMID:  24832869
          Sirisaengtaksin N., M. Gireud, Q. Yan, Y. Kubota, D. Meza, J. Waymire, P.E. Zage, and A.J. Bean.  2014.  UBE4B Couples Ubiquitination and Sorting Machineries to Enable EGFR Degradation.  Journal of Biological Chemistry.  289: 3026-39. PMID: 24344129
           Zage, P.E.*, N. Sirisaengtaksin*, Y. Liu, M. Gireud, B.S. Brown, S. Palla, K.N. Richards, D.P.M. Hughes, and A.J. Bean.  2013.  UBE4B Levels Are Correlated with Clinical Outcomes in Neuroblastoma Patients and with Altered Neuroblastoma Cell Proliferation and Sensitivity to EGFR Inhibitors.  Cancer.  119:  915-23.  PMID:  22990745
           Zage, P.E.*, R. Nolo*, W. Fang, J. Stewart, G. Garcia-Manero, and P.A. Zweidler-McKay.  2012.  Notch Pathway Activation Induces Neuroblastoma Tumor Cell Growth Arrest.  Pediatric Blood & Cancer.  58: 682-9.  PMID:  21744479
           Levy, A.G.*, P.E. Zage*, L.J. Akers, M.L. Ghisoli, Z. Chen, W. Fang, S. Kannan, T. Graham, L. Zeng, R. Nolo, A.R. Franklin, P. Huang, and P.A. Zweidler-McKay.  2012.  The Combination of the Novel Glycolysis Inhibitor 3-BrOP and Rapamycin is Effective Against Neuroblastoma.  Investigational New Drugs.  30: 191-9.  PMID:  20890785.
            Singh, A., C. Rokes, M. Gireud, S. Fletcher, J. Baumgartner, G. Fuller, J. Stewart, P. Zage, and V. Gopalakrishnan.  2011.  Retinoic Acid Induces REST Degradation and Neuronal Differentiation by Modulating the Expression of SCF-TRCP in Neuroblastoma Cells.  Cancer.  117: 5189-202.  PMID:  21523764.
             Zage, P.E., T. Graham, L. Zeng, W. Fang, C. Pien, K. Thress, C. Omer, J.L. Brown, and P.A. Zweidler-McKay.  2011.  The Selective Trk Inhibitor AZ623 Inhibits BDNF-Mediated Neuroblastoma Cell Proliferation and Signaling and Is Synergistic with Topotecan.  Cancer.  117: 1321-9.  PMD: 20960503
             Richards, K.N., P.A. Zweidler-McKay, N. Van Roy, F. Speleman, J. Trevino, P.E. Zage, and D.P.M. Hughes.  2010.  Signaling of ERBB Receptor Tyrosine Kinases Promotes Neuroblastoma Growth In Vitro and In Vivo.  Cancer. 116: 3233-43.  PMID:  20564646.
             Nilsson, M.B, P.E. Zage, L. Zeng, L. Xu, T. Cascone, H.K. Wu, B. Saigal, P.A. Zweidler-McKay, and J.V. Heymach.  2010.  Multiple Receptor Tyrosine Kinases Regulate HIF-1 and HIF-2 in Normoxia and Hypoxia in Neuroblastoma:  Implications for Antiangiogenic Mechanisms of Multikinase Inhibitors.  Oncogene.  29(20): 2938-49.  PMID:  20208561
             Zage P.E., L. Zeng, S. Palla, W. Fang, M.B. Nilsson, J.V. Heymach, and P.A. Zweidler-McKay.  2010.  A Novel Therapeutic Combination for Neuroblastoma:  the VEGFR/EGFR/RET Inhibitor Vandetanib with 13-cis-Retinoic Acid.  Cancer. 116(10): 2465-75.  PMID:  20225331
             Thress, K., T. MacIntyre, H. Wang, D. Whitston, Z.-Y. Liu, E. Hoffman, T. Wang, J.L. Brown, K. Webster, C. Omer, P.E. Zage, L. Zeng, and P.A. Zweidler-McKay.  2009.   Identification and Preclinical Characterization of AZ-23, a Novel, Selective, and Orally Bioavailable Inhibitor of the Trk Kinase Pathway.  Molecular Cancer Therapeutics.  8(7):  1818-27.  PMID 19509272
             Yang, Q., P.E. Zage, D. Kagan, Y. Tian, R. Seshadri, H.R. Salwen, S. Liu, A. Chlenski, and S.L. Cohn.  2004.  Association of Epigenetic Inactivation of RASSF1A with Poor Outcome in Human Neuroblastoma.  Clinical Cancer Research.  10:  8493-500.  PMID:  15623630